==============================
TICKER: WVE
==============================

Role: Momentum hedge fund analyst. You are running a probability audit (NOT a price predictor).
Objective: Decide if WVE has >60% probability of achieving +10% within 30 calendar days.

Hard constraints:
- You MUST penalize "Unknown" earnings + missing headlines (no assuming hidden catalysts).
- You MUST still score based on tape structure: RVOL, ATR%, RSI, distance to 52W high, setup type.
- You MUST output at most 2 BUY ratings across the entire batch (if you are given multiple tickers).
- If catalyst data is weak, default to WATCH/IGNORE even if technicals look good.
- If Dilution risk flag = 1 (headline scan), cap Verdict at WATCH unless there is a clear positive catalyst that outweighs it.
- For Breakouts, require structural confirmation: Above_MA20=1 and Above_MA50=1; otherwise downgrade Technical Alignment.

Inputs:
Market regime snapshot (best-effort):
- SPY=681.62 vs MA20=672.91 (OK); VIX=16.66 (<= 25.00 is OK).
- Regime Gate OK: True

Earnings (best-effort): Unknown

Screener metrics:
- Last: 18.52
- RVOL: 15.28
- ATR%: 6.68 (≈ $1.24 ATR/day)
- RSI14: 90.6
- Dist_to_52W_High%: 5.51

- MA20: 7.77
- MA50: 7.72
- Above_MA20: 1 (1=yes, 0=no)
- Above_MA50: 1 (1=yes, 0=no)
- Ret20d%: 135.62%
- Setup: Breakout
- Score: 50.34
- Leveraged ETF: NO
- Source tags: BASE_UNIVERSE
- Dilution risk flag (headline scan): 1
- Catalyst tags (headline scan): fda,upgrade


Catalyst completeness (penalize Unknowns):
- Completeness Score: 50/100
- Earnings known: False (earnings=Unknown)
- Recent headline count (14d): 7
- Manual headlines: False
- Penalties:
  * Earnings date Unknown (penalize catalyst clarity).


Recent headlines:
- [2026-01-06 21:28 UTC] : Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss
- [2026-01-06 16:26 UTC] : Zepbound Boost Gets a Lift From Arrowhead’s Drug. The Question Is Whether Patients Will Pay.
- [2026-01-06 14:09 UTC] : Assessing Wave Life Sciences (WVE) Valuation After A Sharp Share Price Rebound
- [2026-01-06 12:06 UTC] : Three Genomics Stocks Worth Tracking This Year
- [2026-01-02 15:50 UTC] : Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target
- [2025-12-31 16:25 UTC] : Wave Life Sciences’ (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss
- [2025-12-31 04:46 UTC] : H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE)
- [2025-12-25 06:29 UTC] : What New Catalysts Are Rewriting the Narrative for Wave Life Sciences?
- [2025-12-23 03:18 UTC] : Oppenheimer and Truist Lift Wave Life Sciences Ltd. (WVE) Price Targets After Positive Trial
- [2025-12-17 14:45 UTC] : Share Offerings Prompt Huge Insider Buying in These 3 Biotechs

Standard trade plan template (by setup):
- Entry: Break & hold above prior day high OR key resistance on ≥1.5× volume; avoid chasing if >2× ATR extension.
- Stop: 1.2× ATR below breakout level (or below prior day low if tighter and logical).
- TPs: TP1 = +1.0× ATR, TP2 = +2.0× ATR; trail stop after TP1.
- Position sizing: risk 1–2% of account per trade. Shares = (AccountRisk$) / (StopDistance$).


If data is missing, explicitly state Unknown and list checks:
- Confirm next earnings date (company IR site / Nasdaq earnings calendar).
- Check upcoming: FDA/clinical readouts, contracts, secondary offering/ATM, lockup expiry, guidance updates.
- Check technical context: multi-year resistance, gap levels, supply zones, post-earnings drift behavior.

Scoring rubric (0–100):
- Catalyst Immediacy (0–30)
- Narrative Velocity (0–25)
- Volatility Fit (0–20)
- Technical Alignment (0–25)

Output format (STRICT):
- Total Score: X/100
- Verdict: BUY / WATCH / IGNORE
- Setup: Breakout or Reversal
- 1-line Spark: what specifically could trigger +10%
- 1-line Trap: what invalidates the thesis
- Trade Plan: entry trigger, stop anchor, TP1/TP2, position size rule (risk 1–2%)


==============================
TICKER: CVNA
==============================

Role: Momentum hedge fund analyst. You are running a probability audit (NOT a price predictor).
Objective: Decide if CVNA has >60% probability of achieving +10% within 30 calendar days.

Hard constraints:
- You MUST penalize "Unknown" earnings + missing headlines (no assuming hidden catalysts).
- You MUST still score based on tape structure: RVOL, ATR%, RSI, distance to 52W high, setup type.
- You MUST output at most 2 BUY ratings across the entire batch (if you are given multiple tickers).
- If catalyst data is weak, default to WATCH/IGNORE even if technicals look good.
- If Dilution risk flag = 1 (headline scan), cap Verdict at WATCH unless there is a clear positive catalyst that outweighs it.
- For Breakouts, require structural confirmation: Above_MA20=1 and Above_MA50=1; otherwise downgrade Technical Alignment.

Inputs:
Market regime snapshot (best-effort):
- SPY=681.62 vs MA20=672.91 (OK); VIX=16.66 (<= 25.00 is OK).
- Regime Gate OK: True

Earnings (best-effort): Unknown

Screener metrics:
- Last: 447.98
- RVOL: 4.07
- ATR%: 4.81 (≈ $21.55 ATR/day)
- RSI14: 85.4
- Dist_to_52W_High%: 1.97

- MA20: 351.02
- MA50: 348.14
- Above_MA20: 1 (1=yes, 0=no)
- Above_MA50: 1 (1=yes, 0=no)
- Ret20d%: 47.37%
- Setup: Breakout
- Score: 25.66
- Leveraged ETF: NO
- Source tags: BASE_UNIVERSE
- Dilution risk flag (headline scan): 0
- Catalyst tags (headline scan): upgrade


Catalyst completeness (penalize Unknowns):
- Completeness Score: 55/100
- Earnings known: False (earnings=Unknown)
- Recent headline count (14d): 10
- Manual headlines: False
- Penalties:
  * Earnings date Unknown (penalize catalyst clarity).


Recent headlines:
- [2026-01-13 04:37 UTC] : 1 Momentum  Stock with Competitive Advantages and 2 That Underwhelm
- [2026-01-12 17:47 UTC] : Jim Cramer Calls Ralph Lauren a “Terrifically Well-Run” Company
- [2026-01-12 17:22 UTC] : 2026 Just Started and Carvana Stock Is Already Up Sharply. Can It Keep Soaring?
- [2026-01-12 16:43 UTC] : Why CarMax Stock Slipped 53% In 2025
- [2026-01-11 08:10 UTC] : Carvana (CVNA) Is Up 15.7% After S&P 500 Inclusion And Rising Institutional Sponsorship
- [2026-01-10 14:08 UTC] : Is It Too Late To Consider Carvana (CVNA) After A 140% One-Year Surge?
- [2026-01-09 17:00 UTC] : Carvana (CVNA) Upgraded to Buy: Here's Why
- [2026-01-09 16:31 UTC] : Why Carvana (CVNA) Stock Is Trading Up Today
- [2026-01-09 13:42 UTC] : Carvana (CVNA) Rose as It Exceeded the Investor Expectations
- [2026-01-08 13:01 UTC] : BofA names top stocks as 2026 Tax Refunds set to see strong growth

Standard trade plan template (by setup):
- Entry: Break & hold above prior day high OR key resistance on ≥1.5× volume; avoid chasing if >2× ATR extension.
- Stop: 1.2× ATR below breakout level (or below prior day low if tighter and logical).
- TPs: TP1 = +1.0× ATR, TP2 = +2.0× ATR; trail stop after TP1.
- Position sizing: risk 1–2% of account per trade. Shares = (AccountRisk$) / (StopDistance$).


If data is missing, explicitly state Unknown and list checks:
- Confirm next earnings date (company IR site / Nasdaq earnings calendar).
- Check upcoming: FDA/clinical readouts, contracts, secondary offering/ATM, lockup expiry, guidance updates.
- Check technical context: multi-year resistance, gap levels, supply zones, post-earnings drift behavior.

Scoring rubric (0–100):
- Catalyst Immediacy (0–30)
- Narrative Velocity (0–25)
- Volatility Fit (0–20)
- Technical Alignment (0–25)

Output format (STRICT):
- Total Score: X/100
- Verdict: BUY / WATCH / IGNORE
- Setup: Breakout or Reversal
- 1-line Spark: what specifically could trigger +10%
- 1-line Trap: what invalidates the thesis
- Trade Plan: entry trigger, stop anchor, TP1/TP2, position size rule (risk 1–2%)


==============================
TICKER: ACLX
==============================

Role: Momentum hedge fund analyst. You are running a probability audit (NOT a price predictor).
Objective: Decide if ACLX has >60% probability of achieving +10% within 30 calendar days.

Hard constraints:
- You MUST penalize "Unknown" earnings + missing headlines (no assuming hidden catalysts).
- You MUST still score based on tape structure: RVOL, ATR%, RSI, distance to 52W high, setup type.
- You MUST output at most 2 BUY ratings across the entire batch (if you are given multiple tickers).
- If catalyst data is weak, default to WATCH/IGNORE even if technicals look good.
- If Dilution risk flag = 1 (headline scan), cap Verdict at WATCH unless there is a clear positive catalyst that outweighs it.
- For Breakouts, require structural confirmation: Above_MA20=1 and Above_MA50=1; otherwise downgrade Technical Alignment.

Inputs:
Market regime snapshot (best-effort):
- SPY=681.62 vs MA20=672.91 (OK); VIX=16.66 (<= 25.00 is OK).
- Regime Gate OK: True

Earnings (best-effort): Unknown

Screener metrics:
- Last: 74.08
- RVOL: 3.02
- ATR%: 7.77 (≈ $5.76 ATR/day)
- RSI14: 28.3
- Dist_to_52W_High%: 21.25

- MA20: 80.56
- MA50: 83.91
- Above_MA20: 0 (1=yes, 0=no)
- Above_MA50: 0 (1=yes, 0=no)
- Ret20d%: -14.41%
- Setup: Reversal
- Score: 25.52
- Leveraged ETF: NO
- Source tags: BASE_UNIVERSE
- Dilution risk flag (headline scan): 1
- Catalyst tags (headline scan): earnings,fda,product,upgrade


Catalyst completeness (penalize Unknowns):
- Completeness Score: 25/100
- Earnings known: False (earnings=Unknown)
- Recent headline count (14d): 0
- Manual headlines: False
- Penalties:
  * Earnings date Unknown (penalize catalyst clarity).
  * No recent headlines found (penalize narrative visibility).


Recent headlines:
- [2025-12-24 00:14 UTC] : Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR‑T Program
- [2025-12-22 14:47 UTC] : Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls
- [2025-12-22 13:12 UTC] : Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More
- [2025-12-11 12:44 UTC] : Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
- [2025-12-09 20:31 UTC] : Cancer Study Buoys These Small Biotechs
- [2025-12-08 07:07 UTC] : Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans
- [2025-11-30 10:42 UTC] : CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
- [2025-11-07 20:10 UTC] : How Investors Are Reacting To Arcellx (ACLX) Missing Revenue Estimates and Reporting Wider Losses
- [2025-11-05 22:10 UTC] : Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates
- [2025-11-04 12:45 UTC] : Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates

Standard trade plan template (by setup):
- Entry: Reclaim MA20 (or prior swing level) AND RSI curl up; confirm with a green day + elevated volume.
- Stop: Below recent swing low OR 1.0–1.3× ATR below entry (whichever is tighter and logical).
- TPs: TP1 = MA50 / prior supply zone, TP2 = gap-fill / next resistance; reduce into strength.
- Position sizing: risk 1–2% of account per trade. Shares = (AccountRisk$) / (StopDistance$).


If data is missing, explicitly state Unknown and list checks:
- Confirm next earnings date (company IR site / Nasdaq earnings calendar).
- Pull 14–30d headlines from a second source (SEC, PR, major outlets, terminal).
- Check upcoming: FDA/clinical readouts, contracts, secondary offering/ATM, lockup expiry, guidance updates.
- Check technical context: multi-year resistance, gap levels, supply zones, post-earnings drift behavior.

Scoring rubric (0–100):
- Catalyst Immediacy (0–30)
- Narrative Velocity (0–25)
- Volatility Fit (0–20)
- Technical Alignment (0–25)

Output format (STRICT):
- Total Score: X/100
- Verdict: BUY / WATCH / IGNORE
- Setup: Breakout or Reversal
- 1-line Spark: what specifically could trigger +10%
- 1-line Trap: what invalidates the thesis
- Trade Plan: entry trigger, stop anchor, TP1/TP2, position size rule (risk 1–2%)
